UCB’s Neupro Returns To U.S. Market With New Formulation, Indications
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA approves a new version of UCB’s skin patch for treatment of advanced Parkinson’s disease and restless leg syndrome. The new product, which contains different excipients to prevent crystallization, will be available in July.